Torrent Pharmaceuticals Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on July 28, 2025
TORNTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Torrent Pharmaceuticals held its 52nd AGM on July 28, 2025 via video conferencing, and all 12 resolutions were approved by shareholders with overwhelming majorities (over 97% in favour of each). Shareholders confirmed a final dividend of ₹6 per share on top of the ₹26 per share interim dividend already paid for FY25, taking the total dividend to ₹32 per share. Aman Mehta was re-appointed as a Director and also appointed as Managing Director (99.80% in favour), with his remuneration approved at 97.41% — the lowest approval margin, with 2.59% dissent. The company also secured shareholder approval to raise its borrowing limit from ₹15,000 crore to ₹26,000 crore (99.53%) and to issue equity shares or convertible bonds/debentures as needed (100%).
All resolutions passing cleanly removes governance uncertainty and clears the way for Torrent Pharma to tap larger debt (up to ₹26,000 crore) and potentially raise equity capital in the future. The confirmed ₹32 total dividend per share for FY25 provides clear income for shareholders. The slight dissent on the MD's remuneration (2.59%) is minor and unlikely to affect the stock; overall the meeting signals strong shareholder support for the company's growth and capital plans.